| Designations: | JVM-2 |
|
|
| Depositors: | J.V.Melo |
|
|
| Biosafety Level: | 2 |
|
|
| Shipped: | frozen |
|
|
| Medium & Serum: | See Propagation |
|
|
| Growth Properties: | suspension |
|
|
| Organism: | Homo sapiens (human) |
|
|
| Morphology: | lymphoblast
JVM-2 EB細胞，病毒感染的人外周淋巴細胞Characterization Data |
|
|
| Source: | Organ: peripheral blood
Cell type: lymphoblast; immortalized with Epstein-Barr virus (EBV); Epstein-Barr virus (EBV) transformed
Disease: Mantle Cell Lymphoma |
|
|
| Permits/Forms: | In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimay responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location. |
|
|
|
| Oncogene: | p53 [PubMed: 16434365] |
|
|
| Antigen Expression: | CD3-, CD5-, CD10-, CD19+, CD20+, CD23+ (verified at ATCC ) |
|
|
| DNA Profile (STR): | Amelogenin: X CSF1PO: 11 D13S317: 11,13 D16S539: 12,13 D5S818: 11,12 D7S820: 10,11 THO1: 6,9 TPOX: 8,11 vWA: 17 |
|
|
| Cytogenetic Analysis: | Bimodal chromosome number: 46 and 92 This is a bimodal female cell line with approximay half the cells being pseudodiploid and the other half pseudotetraploid. Most cells contain the t(11;14)(q13;q32) derivative chromosome common to Mantle Cell Lymphoma. Other derivative chromosomes included: t(3;8)(q13;p21), add(4q) [or t(4;13)(q2?5;q1?4)], del(13)(q21) and dup(16p). |
|
|
| Age: | 63 |
|
|
| Gender: | female |
|
|
| Ethnicity: | Caucasian |
|
|
| Comments: | Leukemic cells from a patient with B-prolymphocytic leukemia were immortalized in vitro with Epstein-Barr virus (EBV) in the presence of phorbol-ester, TPA. JVM-2 is characterized cytogenetically by t(11;14)(q13; q32) [PubMed: 3093393 and 3262465]. JVM-2 cells retain p16 expression and exhibit low expression of cyclin D1. This cell line expresses cyclin D2 [PubMed: 16183118]. Based on the new classification of lymphomas, JVM-2 is considered a Mantle Cell Lymphoma (MCL) [PubMed: 16183118 and PubMed: 15229187]. |
|
|
| Propagation: | ATCC complete growth medium: The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, Catalog No. 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
Temperature: 37.0°C
Atmosphere: air, 95%; carbon dioxide (CO2), 5% |
|
|
| Subculturing: | Cultures can be maintained by addition of fresh medium. Alternatively, cultures can be established by centrifugation with subsequent resuspension at 1 x 10(4) to 3 x 10(4) viable cells/ml. Do not allow the cell concentration to exceed 1 X 10(6) cells/ml. |
|
|
| Preservation: | 70% growth medium; 20% FBS; 10% DMSO |
|
|
| Doubling Time: | about 48 hours |
|
|
| References: | 92892: Melo JV, et al. Two new cell lines from B-prolymphocytic leukaemia: characterization by morphology, immunological markers, karyotype and Ig gene rearrangement. Int. J. Cancer 38: 531-538, 1986. PubMed: 3093393
92895: Salaverria I, et al. Mantle cell lymphoma: from pathology and molecular pathogenesis to new therapeutic perspectives. Haematologica 91: 11-16, 2006. PubMed: 16434365
16172638: de Leeuw RJ, et al. Comprehensive whole genome array CGH profiling of mantle cell lymphoma model genomes. Hum Mol Genet.: 1;13(17):1827-37 ( 2004). PubMed: 15229187.
16172639: Tucker, C.A., et al. Four human t(11;14)(q13;q32)-containing cell lines having classic and variant features of Mantle Cell Lymphoma. Leuk Res. 30(4): 449-457, 2006. PubMed: 16183118. |
